{"analyses":[{"ciLowerLimit":"0.58","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.83","estimateComment":"The HR and 95% CI was based on a stratified Cox proportional hazards regression model, stratified by baseline ECOG performance status, region and liver metastases as per IWRS.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.69","statisticalMethod":"Stratified log-rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.0","upperLimit":"7.7","value":"7.4"},{"groupId":"OG001","lowerLimit":"5.3","upperLimit":"5.8","value":"5.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"259"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of randomization to the first documented disease progression using response evaluation criteria in solid tumors (RECIST) Version 1.1 as per Investigator assessment or death due to any cause. The median PFS was measured using Kaplan-Meier technique.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were treated with irinotecan liposome injection 50 mg/m\\^2 followed by oxaliplatin 60 mg/m\\^2, followed by LV 400 mg/m\\^2 and then 5-FU 2400 mg/m\\^2 IV infusion on Days 1 and 15 of each 28-day cycle until disease progression, death, unacceptable study treatment-related toxicity or withdrawal of consent.","id":"OG000","title":"NALIRIFOX"},{"description":"Participants were treated with nab-paclitaxel 125 mg/m\\^2 followed by gemcitabine 1000 mg/m\\^2 IV on Days 1, 8 and 15 of each 28-day cycle until disease progression, death, unacceptable study treatment-related toxicity or withdrawal of consent.","id":"OG001","title":"Nab-paclitaxel+Gemcitabine"}],"paramType":"MEDIAN","populationDescription":"The ITT population consisted of all randomized participants to whom study treatment was assigned by randomization. Only participants with PFS event are reported.","reportingStatus":"POSTED","timeFrame":"Assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose up to PCD of 23 July 2022 (maximum of 893 days)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}